Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

OCREVUS treatment significantly slowed accumulation of atrophied T2-lesion volume (aT2-LV) compared with placebo at 120 weeks in a post-hoc analysis of the ORATORIO study in PPMS (319 mm3 vs. 366 ...

Biogen (NASDAQ:BIIB) was downgraded to hold from buy by Jefferies, due in part to a looming royalty cut for the multiple sclerosis drug Ocrevus. Jefferies said it downgraded the stock on three ...

OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without IV infrastructure or with IV constraints, like at a doctor's officeThis approval is backed by a decade of proven ...

Genentech, a member of the Roche Group, today announced that new Ocrevus ® data and continued research into neuromyelitis optica spectrum disorder will be presented at the 38 th Congress of the ...

New safety data as of January 2020 will be presented, representing 5,680 patients with RMS and PPMS and 18,218 patient-years of exposure to Ocrevus, across all Ocrevus clinical trials.

As Ocrevus is given twice a year once, after two initial infusions two weeks a part, this points to a cost of just under £10,000 per infusion, although Scholtz would not give a precise figure.

Ocrevus is a humanized monoclonal antibody that works by targeting CD20-positive B cells, a type of immune cell thought to contribute to myelin and axonal damage. It is available as 300mg/10mL ...

OCREVUS significantly reduced the proportion of people with RMS who experienced Progression Independent of Relapse Activity (PIRA) in a post-hoc analysis compared to Rebif® (interferon-beta 1a).

Roche’s new drug Ocrevus has landed in the same sentence with the three letters all makers of multiple sclerosis drugs dread: PML. For the first time, a patient taking the Roche product has been ...

OCREVUS is the number one prescribed MS medication in the U.S. for patients starting a new treatment, and more than 200,000 people have now been treated with OCREVUS globally.